RxDoctor Payments Data

Alexander Dagum, MD

Plastic and Reconstructive Surgery · Garden City, NYNPI 1487673091

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,000 of the $4,859 with a category attached, or 61.7%. Akcea Therapeutics, Inc. accounts for 61.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $3,023 and has fallen 81.2% since, to $570 in 2025.

$4,859in general payments, 2019–2025

Across 31 payments — averaging $156.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$3K
  • Stryker$445
  • Integra Lifesciences Corporation$301
  • Axogen$284
  • Avita Medical Americas, LLC$163
  • Access Pro Medical, LLC$150
  • plus $516 from 10 others
$1,750in research payments, 2019–2025

Across 1 payment — averaging $1750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$2K

What the payments were for

  • Consulting fees$3,00062%
  • Food & beverage$1,85938%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,859 in reported general payments places this provider in the 75th percentile of 219 plastic and reconstructive surgery providers in New York.

See all plastic and reconstructive surgery providers in New York

Medicare billing

Part B allowed, 2024
$170,599
Medicare patients
209
Services billed
1,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate36$286

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →